Mevrometostat

Phase 3Small molecule

Mevrometostat is one of 4 small molecule programs targeting Castration Sensitive Prostate Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Castration Sensitive Prostate CancerRecruiting

Castration Sensitive Prostate CancerPhase 3

Recruiting

Competition

Competitive Landscape

4 competitors in Castration Sensitive Prostate Cancer

#DrugCompanyPhaseTrials

Xtandi

Astellas

Phase 3

1 2

Yervoy

Bristol-Myers Squibb

Phase 2

1 3

Firmagon

Ferring

Phase 2

1 4

Mevrometostat

Pfizer

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2034

Phase 3Recruiting

Castration Sensitive Prostate Cancer

NCT07028853

Clinical

Trials by Indication[1]

Castration Sensitive Prostate Cancer1 trial

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)

Recruiting· Pfizer logo

Pfizer·Phase 3·NCT07028853·1,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Mevrometostat. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Mevrometostat compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Mevrometostat. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

Mevrometostat

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2034

Trials by Indication[1]

Castration Sensitive Prostate Cancer1 trial

References

Drug Info

Quick Facts

Related News